CD178 (Fas Ligand) Monoclonal Antibody (MFL3), PE, eBioscience™ | Invitrogen 12-5911-83 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

CD178 (Fas Ligand) Monoclonal Antibody (MFL3), PE, eBioscience™

catalog :

12-5911-83

quantity :

200 µg

price :

US 354

clonality :

monoclonal

host :

hamsters

conjugate :

clone name :

MFL3

reactivity :

mouse

application :

flow cytometry

citations: 14

Reference
Cobbold S, Adams E, Howie D, Waldmann H. CD4+ T Cell Fate Decisions Are Stochastic, Precede Cell Division, Depend on GITR Co-Stimulation, and Are Associated With Uropodium Development. Front Immunol. 2018;9:1381 pubmed publisher
Deng R, Hurtz C, Song Q, Yue C, Xiao G, Yu H, et al. Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. Nat Commun. 2017;8:978 pubmed publisher
Frenkel D, Zhang F, Guirnalda P, Haynes C, Bockstal V, Radwanska M, et al. Trypanosoma brucei Co-opts NK Cells to Kill Splenic B2 B Cells. PLoS Pathog. 2016;12:e1005733 pubmed publisher
Wu Y, Pfeifer A, Myschetzky R, Garbyal R, Rasmussen P, Knigge U, et al. Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor. Diagnostics (Basel). 2013;3:344-55 pubmed publisher
Zhang J, Han C, Dai H, Hou J, Dong Y, Cui X, et al. Hypoxia-Inducible Factor-2Î± Limits Natural Killer T Cell Cytotoxicity in Renal Ischemia/Reperfusion Injury. J Am Soc Nephrol. 2016;27:92-106 pubmed publisher
Song L, Yang M, Knoff J, Wu T, Hung C. Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment. PLoS ONE. 2014;9:e115711 pubmed publisher
Tassi I, Claudio E, Wang H, Tang W, Ha H, Saret S, et al. The NF-ÎºB regulator Bcl-3 governs dendritic cell antigen presentation functions in adaptive immunity. J Immunol. 2014;193:4303-11 pubmed publisher
Yang F, Wei Y, Cai Z, Yu L, Jiang L, Zhang C, et al. Activated cytotoxic lymphocytes promote tumor progression by increasing the ability of 3LL tumor cells to mediate MDSC chemoattraction via Fas signaling. Cell Mol Immunol. 2015;12:66-76 pubmed publisher
Qin X, Liu X, Shan B, Shi L, Sharma S, Wu J, et al. Inhibition of eIF5A results in aberrant uterine natural killer cell function and embryo loss in mice. Am J Reprod Immunol. 2014;71:229-40 pubmed publisher
Riese M, Wang L, Moon E, Joshi R, Ranganathan A, June C, et al. Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. Cancer Res. 2013;73:3566-77 pubmed publisher
Zou Y, Chen T, Han M, Wang H, Yan W, Song G, et al. Increased killing of liver NK cells by Fas/Fas ligand and NKG2D/NKG2D ligand contributes to hepatocyte necrosis in virus-induced liver failure. J Immunol. 2010;184:466-75 pubmed publisher
Cheng L, You Q, Yin H, Holt M, Franklin C, Ju C. Effect of polyI:C cotreatment on halothane-induced liver injury in mice. Hepatology. 2009;49:215-26 pubmed publisher
Huang B, Mao C, Peng S, Hung C, Wu T. RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency. Hum Gene Ther. 2008;19:763-73 pubmed publisher
McKinstry K, Golech S, Lee W, Huston G, Weng N, Swain S. Rapid default transition of CD4 T cell effectors to functional memory cells. J Exp Med. 2007;204:2199-211 pubmed

product information

Product Type :

Antibody

Product Name :

CD178 (Fas Ligand) Monoclonal Antibody (MFL3), PE, eBioscience™

Catalog # :

12-5911-83

Quantity :

200 µg

Price :

US 354

Clonality :

Monoclonal

Purity :

Affinity chromatography

Host :

Armenian Hamster

Reactivity :

Mouse

Applications :

Flow Cytometry: 1 µg/test

Species :

Mouse

Clone :

MFL3

Isotype :

IgG

Storage :

4° C, store in dark, DO NOT FREEZE!

Description :

CD178 (Fas ligand, FasL) is a type-II-membrane protein, whose N-terminus is in the cytoplasm and its C-terminal region extends into the extracellular space. Its receptor, FasR, is a cell-surface-type-I-membrane protein and a member of the tumor necrosis factor (TNF) and nerve growth factor (NGF) receptor family. As a member of the TNF-cytokine family CD178 induces apoptosis when interacting with FasR. CD178 may exist as either membrane bound (45 kD) or soluble forms (26 kD). The soluble protein can be released from cells upon cleavage by metalloproteinases. Binding of CD178 to Fas leads to oligomerization of the receptor and triggers apoptotic cell death through the interaction of other proteins. CD178 is predominantly expressed in activated T-lymphocytes and natural killer (NK) cells also it is expressed in the tissues of immune-privilege sites such as testis and eye. CD178 expression is also reported in various tissues as thymus, liver, ovary, lung, heart and kidney. It is assumed that induction of apoptosis through CD178 is predominantly involved in anti-viral immune responses. CD178 is a cell surface molecule belonging to the tumor necrosis factor family, binds to its receptor Fas, thus inducing apoptosis. Various cells express FAS, where CD178 is expressed predominantly on activated T cells. FAS and CD178 are involved in the down-regulation of immune reactions as well as T cell-mediated cytotoxicity. CD178 concentration has also been shown to be associated with atherosclerosis and inflammatory disease, in patients with hypertension. The Fas/ CD178 system has been shown to play a role in a number of human diseases, for example AIDS, hepatitis or cancer.

Format :

Liquid

Applications w/Dilutions :

Flow Cytometry: 1 µg/test

Aliases :

ADAM10-processed FasL form; ALPS1B; APL; apoptosis (APO-1) antigen ligand 1; Apoptosis (APO-1) antigen ligand 1 (Fas antigen ligand); apoptosis antigen ligand; APT1LG1; APTL; CD178; CD95 ligand; CD95L; CD95-L; CD95L protein; fas antigen ligand; Fas ligand; Fas ligand (TNF superfamily, member 6); Fasl; Fas-L; FasL ICD; FasL intracellular domain; Faslg; Fas-LG; generalized lymphoproliferative disease; gld; mutant tumor necrosis factor family member 6; Receptor-binding FasL ectodomain; sFasL; Soluble Fas ligand; SPA; SPPL2A-processed FasL form; TNFL; Tnfsf6; TNLG1A; Tumor necrosis factor (ligand) superfamily member 6 (apoptosis (APO-1) antigen ligand 1) (Fas antigen ligand); Tumor necrosis factor (ligand) superfamily, member 6 (apoptosis (APO-1) antigen ligand 1) (Fas antigen ligand); Tumor necrosis factor ligand; tumor necrosis factor ligand 1A; tumor necrosis factor ligand superfamily member 6; Tumor necrosis factor ligand superfamily member 6, membrane form; Tumor necrosis factor ligand superfamily member 6, soluble form